Advancements in Nanoparticle-Based Drug Delivery Systems A Paradigm Shift in Therapeutics

Abdalla Gouma Ali[1*], Akram Mohamed Ahmed Salih Adam[1], Fadul Abdelrahman Musa[1], Mazin Salih Abdalla Mohamed[1], Omer Siddig Ahmed Malik[1]

1. Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Anantapuramu-515721, Andhra Pradesh, India.

***Corresponding Address:**

Abdalla Gouma Ali

Associate Professor

Department of Pharmaceutical Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research, K.R. Palli Cross, Anantapur, Chiyyedu, Andhra Pradesh-515721.

Abstract:

Nanoparticle-based drug delivery systems have revolutionized modern therapeutics by overcoming the limitations of conventional drug delivery methods. These nano-carriers enhance drug solubility, bioavailability, and targeted delivery while minimizing systemic side effects. Various nanoparticles, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, and nanocrystals, offer versatile applications in cancer therapy, gene therapy, vaccine development, and central nervous system drug delivery. Mechanisms such as controlled release, stimuli-responsive behavior, and targeted drug delivery further optimize therapeutic efficiency. However, challenges remain, including potential toxicity, scalability issues, regulatory hurdles, and stability concerns. Advances in personalized nanomedicine, AI-driven nanoparticle design, and multifunctional nanoparticles hold promise for the future. With ongoing research and development, nanoparticle-based drug delivery systems are expected to pave the way for safer, more effective, and patient-specific therapeutic interventions.

Keywords: Nanoparticle-based drug delivery, controlled release, targeted therapy, personalized nanomedicine, theranostics,

1. Introduction

Overview of Drug Delivery Systems (DDS):

Drug delivery systems (DDS) are technological platforms designed to deliver pharmaceutical compounds to specific locations in the body in a controlled and efficient manner(1, 2). Traditional DDS, such as oral tablets, injections, and topical formulations, have been used for decades to treat various diseases. However, these conventional methods face significant limitations in terms of bioavailability, drug stability, and precision in targeting the disease site. For example, oral drugs often undergo significant degradation in the digestive tract, resulting in reduced bioavailability. Similarly, injections can cause local irritation, and systemic distribution often leads to undesirable side effects due to the non-specific distribution of the drug(3). Furthermore, most traditional DDS are unable to deliver the required dose of the drug at a consistent rate over time, which limits their effectiveness and often requires frequent dosing(4).

Need for Advanced Drug Delivery Systems:

The evolving nature of disease treatments, particularly with chronic conditions and complex diseases like cancer, neurological disorders, and autoimmune diseases, has led to the increasing demand for more efficient drug delivery methods(5). These systems aim to improve therapeutic outcomes by ensuring that the right drug reaches the right site at the right time. Advanced DDS are designed to address issues such as poor solubility, low bioavailability, and lack of targeted delivery. For example, in cancer therapy, targeted delivery ensures that the chemotherapy drug is delivered directly to the tumor cells, reducing the damage to surrounding healthy tissues and minimizing side effects(6). Additionally, the demand for sustained-release formulations is growing to improve patient compliance by reducing the frequency of drug administration(7).

Role of Nanoparticles in Drug Delivery:

Nanoparticles have emerged as a promising solution to address the limitations of conventional drug delivery systems. These nano-sized carriers, typically ranging from 1 to 1000 nanometers, can encapsulate a wide range of drugs, including hydrophobic molecules, proteins, nucleic acids, and other therapeutic agents(8). Their small size allows for enhanced tissue penetration, improved cellular uptake, and the ability to cross biological barriers such as the blood-brain barrier(9, 10). Nanoparticles can also be engineered to offer controlled and sustained release, providing therapeutic effects over an extended period(11). Furthermore, their surface can be modified with specific ligands or antibodies to enable targeted drug delivery, ensuring that the drug reaches the desired site while minimizing systemic exposure and reducing side effects(12). Nanoparticle-based DDS are therefore revolutionizing the field of pharmaceutics by enabling more effective, efficient, and safer drug delivery strategies(13).

2. Types of Nanoparticles Used in Drug Delivery

Liposomes:

Liposomes are spherical vesicles made of a lipid bilayer that can encapsulate both hydrophilic and hydrophobic drugs(14). Their structure consists of a hydrophobic inner core surrounded by a hydrophilic outer layer, which makes them ideal for delivering a variety of therapeutic agents(15). Liposomes can carry a wide range of drugs, including anticancer agents, vaccines, and gene therapy molecules. Their ability to encapsulate hydrophobic drugs in the lipid bilayer

and hydrophilic drugs in the aqueous core makes them versatile carriers. Additionally, liposomes can be engineered for specific targeting by attaching ligands to their surface, such as antibodies, peptides, or folic acid, which allows them to bind to specific receptors on target cells(16-18). This targeted drug delivery improves therapeutic efficacy and reduces side effects by minimizing the exposure of healthy tissues to the drug. Liposomes are also capable of achieving controlled and sustained release, providing a prolonged therapeutic effect. Clinical applications include the delivery of anticancer drugs like doxorubicin, as well as vaccines, where liposomes enhance the immunogenic response(19).

Polymeric Nanoparticles:

Polymeric nanoparticles (PNPs) are solid, biodegradable nanoparticles made from synthetic or natural polymers. These nanoparticles are widely used in controlled drug release due to the versatility of polymers in modifying the release rate of encapsulated drugs(20). Common polymers used in PNPs include poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and chitosan(21). The drug release from PNPs can be tailored by adjusting the polymer composition, molecular weight, and cross-linking. Polymeric nanoparticles can also offer enhanced stability for drugs that are unstable or prone to degradation in the body(22). Furthermore, PNPs can be engineered for targeted drug delivery by functionalizing their surface with ligands that recognize specific cell receptors. This ability to target specific tissues or cells, such as cancer cells, enhances the therapeutic index of drugs, reducing off-target effects. Polymeric nanoparticles are used in a wide range of therapeutic applications, including cancer therapy, gene delivery, and vaccine delivery(23).

Solid Lipid Nanoparticles (SLNs):

Solid Lipid Nanoparticles (SLNs) are colloidal particles made of solid lipids that can encapsulate both lipophilic and hydrophilic drugs. SLNs are considered a more stable alternative to liposomes, as they avoid the risks associated with the use of liquid lipids. These nanoparticles offer advantages such as high biocompatibility, controlled drug release, and ease of preparation(24). SLNs are prepared through methods like high-pressure homogenization or solvent evaporation. They provide controlled and sustained release by forming a solid matrix, which reduces the need for frequent dosing(25). Furthermore, SLNs protect sensitive drugs from degradation and oxidation. The potential of SLNs in drug delivery lies in their ability to deliver drugs through the skin (transdermal delivery), to specific tissues via targeting ligands, and to enhance the bioavailability of poorly soluble drugs. SLNs have been used in topical treatments, such as delivering anti-inflammatory agents, as well as in oral drug delivery for poorly water-soluble drugs(26).

Dendrimers:

Dendrimers are highly branched, tree-like polymers with a well-defined, nanoscale structure. Their unique architecture allows for a high degree of functionality on their surface, which can be used for drug loading, targeting, and controlled release(27). Dendrimers consist of a central core, branches, and surface functional groups, which can be modified to enhance drug delivery. One of the key advantages of dendrimers is their precision in drug delivery. The monodisperse nature of dendrimers ensures that each nanoparticle is uniform, which provides consistent drug release(28). Dendrimers can carry a variety of drugs, including small molecules, peptides, and nucleic acids, and are particularly useful for delivering drugs to specific tissues or cells through

targeted surface modification. Their multifunctionality allows for the conjugation of targeting ligands, imaging agents, or therapeutic agents on the same particle, enabling theranostic (therapeutic + diagnostic) applications. Dendrimers have been applied in cancer therapy, gene therapy, and vaccine delivery due to their ability to provide enhanced drug solubility, stability, and targeting(29).

Nanocrystals:

Nanocrystals are nanoparticles that consist of pure drug molecules without any carrier material. These crystals are typically smaller than 1000 nm and are used to enhance the solubility and bioavailability of poorly water-soluble drugs(30). The small size of nanocrystals increases the surface area of the drug, which leads to improved dissolution rates and higher drug absorption in the body. This is especially beneficial for drugs that have low aqueous solubility, which often results in poor bioavailability when administered orally. Nanocrystals can be prepared using methods like high-pressure homogenization, milling, or precipitation. Once formulated, nanocrystals can be administered orally, intravenously, or topically, depending on the drug and the intended application. Nanocrystals are particularly useful for enhancing the bioavailability of drugs in oncology, cardiovascular diseases, and CNS disorders, where improving drug solubility is critical to therapeutic success(31, 32).

Other Nanomaterials (e.g., Micelles, Carbon Nanotubes, Gold Nanoparticles):

Nanomaterials other than liposomes and dendrimers offer unique advantages in drug delivery systems. Micelles are self-assembled nanostructures composed of amphiphilic molecules, where the hydrophobic core can encapsulate poorly soluble drugs, and the hydrophilic outer shell allows for stability in aqueous environments. Micelles are useful in the delivery of anticancer drugs and gene therapy agents due to their ability to solubilize hydrophobic compounds and enhance their bioavailability(33). Carbon nanotubes (CNTs) are cylindrical nanostructures with high surface area and excellent mechanical and electrical properties. They can be functionalized to carry drugs, peptides, or DNA and are being explored for drug delivery to hard-to-reach tissues, such as the brain, due to their ability to cross biological barriers like the blood-brain barrier (BBB)(34, 35). Gold nanoparticles (AuNPs) are biocompatible, versatile, and can be easily functionalized with various molecules, including drugs, antibodies, or imaging agents. They are widely used in cancer therapy, diagnostics, and theranostic applications, where their optical properties enable enhanced detection and monitoring of drug delivery. These nanomaterials, with their unique properties, expand the range of drug delivery options, offering high specificity, multifunctionality, and enhanced therapeutic effects(36).

3. Mechanisms of Drug Release from Nanoparticles

Controlled Release Systems:

Controlled release systems are designed to release a drug at a predetermined rate, maintaining therapeutic drug concentrations over an extended period, reducing the frequency of drug administration, and minimizing side effects(4). The principle behind controlled release is the formulation of a drug delivery system that modulates the drug's release according to a specific pattern, often following zero-order kinetics. This is achieved through various mechanisms, such as diffusion, swelling, or degradation of the drug carrier. In solid polymeric nanoparticles, for instance, the drug is encapsulated within a polymer matrix that slowly degrades over time, allowing for the sustained release of the drug. Another common approach uses diffusion-

controlled systems, where the drug diffuses through the carrier material at a controlled rate. Controlled release systems significantly improve patient compliance by reducing the need for frequent dosing. They also enhance therapeutic efficacy by ensuring constant drug levels in the bloodstream, which is particularly beneficial for drugs with short half-lives or drugs that require continuous, low-level exposure. These systems are widely used in various therapeutic areas, including chronic diseases like hypertension and diabetes, where maintaining steady drug concentrations is critical for effective treatment(37).

Stimuli-Responsive Nanoparticles:

Stimuli-responsive nanoparticles are engineered to release their drug payload in response to specific external or internal triggers, offering the potential for "on-demand" drug release(38). These nanoparticles can be designed to react to changes in environmental factors such as pH, temperature, enzymes, or magnetic fields. pH-responsive nanoparticles exploit the differences in pH between healthy tissues and disease sites, such as tumors or inflamed areas, to release the drug at the targeted location(39). Temperature-sensitive nanoparticles are designed to release their cargo when exposed to elevated temperatures, which can be induced locally, for example, using hyperthermia treatments(40). Enzyme-responsive nanoparticles release the drug in the presence of specific enzymes, often found in high concentrations in disease tissues (e.g., matrix metalloproteinases in tumors)(41). Magnetic-responsive nanoparticles can be manipulated with an external magnetic field to release drugs in a controlled manner at the desired site(42). This property is particularly useful for targeting specific organs or tissues, such as the brain, where controlled drug delivery is challenging. These systems offer enhanced drug targeting, reduced side effects, and the ability to tailor the release of therapeutic agents in a spatiotemporally precise manner, making them a promising approach for cancer therapy, gene delivery, and inflammatory diseases(43).

Targeted Drug Delivery Mechanisms:

Targeted drug delivery systems aim to deliver drugs directly to the desired site of action, enhancing therapeutic efficacy and minimizing systemic side effects. There are two primary strategies for targeted drug delivery: passive targeting and active targeting(44).

In passive targeting, nanoparticles are designed to take advantage of the body's natural physiological processes to reach the desired site. One common mechanism of passive targeting is the enhanced permeability and retention (EPR) effect, which occurs in tumor tissues(45). Tumors typically have leaky blood vessels, allowing nanoparticles to passively accumulate at the tumor site. The drug-loaded nanoparticles can then be retained at the tumor for extended periods, improving drug concentration at the site and minimizing off-target effects. Passive targeting is also used in liver targeting, where the reticuloendothelial system (RES) takes up particles of a certain size and composition(46).

Active targeting, on the other hand, involves modifying the surface of nanoparticles with targeting ligands that can specifically bind to receptors overexpressed on the target cells(47). These ligands can be antibodies, peptides, or small molecules that bind to specific receptors on the surface of the target cells, such as folate receptors on cancer cells or insulin receptors in diabetic patients(48). The targeted nanoparticles are then taken up by the cells through receptor-mediated endocytosis, resulting in precise drug delivery to the disease site. Active targeting significantly enhances the specificity and selectivity of drug delivery, reducing the exposure of

healthy tissues to the drug and improving therapeutic outcomes. This approach is widely used in cancer therapy, where targeting specific tumor markers increases the efficiency of chemotherapy drugs and minimizes toxic side effects(49).

4. Innovations in Nanoparticle-Based Drug Delivery

Nanoparticles in Cancer Therapy:

Nanoparticles have revolutionized cancer therapy by enabling targeted drug delivery, improving bioavailability, and overcoming common challenges such as multidrug resistance(50). Recent breakthroughs in nanoparticle-based drug delivery systems have significantly enhanced the ability to target specific tumor markers. By engineering nanoparticles to carry chemotherapeutic agents, such as doxorubicin or paclitaxel, these carriers can be functionalized with ligands like antibodies, peptides, or folate, which bind selectively to overexpressed receptors on cancer cells(51). This targeted approach ensures that the drug is delivered directly to the tumor site, reducing the exposure of healthy cells to the toxic effects of chemotherapy and minimizing side effects. Nanoparticles also offer potential solutions for overcoming drug resistance, which is often caused by the efflux of chemotherapy agents through the overexpression of transport proteins like P-glycoprotein. Nanoparticles can bypass these resistance mechanisms by facilitating intracellular drug accumulation through enhanced permeability and retention (EPR) effects, thus enhancing the efficacy of chemotherapy(45). Additionally, nanoparticles such as liposomes, dendrimers, and solid lipid nanoparticles (SLNs) can be engineered for controlled and sustained drug release, further improving therapeutic outcomes and reducing the need for frequent dosing(25). With the ability to deliver both small molecules and biologics (such as RNA-based therapies or monoclonal antibodies), nanoparticle-based therapies are advancing cancer treatment, providing more effective, personalized, and less toxic alternatives to conventional therapies(52).

Nanoparticles in Gene Therapy:

Gene therapy aims to treat or prevent diseases by delivering genetic material (DNA, RNA) into patients' cells to alter gene expression(53). Nanoparticles play a critical role in this area by serving as efficient delivery vehicles for nucleic acids, offering solutions to the inherent challenges of gene delivery, such as stability, bioavailability, and immune response. DNA and RNA delivery systems, such as lipid nanoparticles (LNPs) and polymeric nanoparticles, can encapsulate the nucleic acid payload, protecting it from degradation while facilitating efficient delivery into cells. One of the most notable applications of nanoparticles in gene therapy has been in mRNA vaccines, where lipid nanoparticles serve as the carrier for mRNA encoding a specific protein to elicit an immune response. These nanoparticles ensure that the mRNA remains stable and is delivered efficiently to the cytoplasm for translation(54). Additionally, CRISPR-based therapies are another area where nanoparticles show great promise. CRISPR-Cas9 gene-editing systems require precise delivery to target specific genes(55). Nanoparticles can protect the CRISPR machinery, including guide RNA and Cas9 proteins, ensuring targeted and safe genome editing(55). Nanoparticle-mediated gene delivery is also highly beneficial in treating genetic disorders, such as cystic fibrosis or Duchenne muscular dystrophy, where the defective gene is repaired or replaced in targeted tissues(56). Through continued innovations in nanoparticle design, gene therapy can become more effective, safe, and widely applicable(57).

Nanoparticles in Vaccine Delivery:

Nanoparticles have opened new possibilities for improving vaccine delivery, formulation, and efficacy. Traditional vaccines often rely on using attenuated or inactivated pathogens, but nanoparticles offer a more customizable and potent solution. Nanoparticle-based vaccine formulations can carry antigens, adjuvants, or both, and provide controlled release, enhancing immune system stimulation(58). Liposomes, polymeric nanoparticles, and micelles are commonly used to encapsulate antigens, ensuring they are delivered to the appropriate immune cells, such as dendritic cells, which are essential for initiating adaptive immunity(59). Additionally, nanoparticles can enhance the stability of vaccines by protecting the antigens from degradation, ensuring that they remain active until they reach the target site. The use of nanoparticles in vaccine delivery has been particularly impactful in developing mRNA vaccines, such as those used for COVID-19(60). Lipid nanoparticles protect the fragile mRNA and facilitate its delivery into cells, where it instructs the body to produce viral proteins and trigger an immune response(61). Moreover, nanoparticles can serve as adjuvants by enhancing the immune response through their surface properties, such as charge, size, and shape. Nanoparticle-based vaccines offer several advantages, including the ability to target specific immune cell populations, enhance vaccine potency, and provide prolonged immunity with lower doses. These advancements in vaccine formulation are paving the way for next-generation vaccines against infectious diseases, cancer, and even autoimmune conditions(62).

Nanoparticles for CNS Drug Delivery:

One of the most significant challenges in drug delivery is the efficient delivery of therapeutic agents to the central nervous system (CNS), primarily due to the blood-brain barrier (BBB), a selective barrier that limits the entry of most drugs into the brain(63). Nanoparticles have emerged as a promising solution for overcoming this obstacle. Their small size allows them to cross the BBB through mechanisms like receptor-mediated endocytosis, transcytosis, and active transport(64). For instance, nanoparticles can be functionalized with ligands such as transferrin, which binds to receptors on the BBB, facilitating transport into the brain. Additionally, nanoparticles such as liposomes, polymeric nanoparticles, and gold nanoparticles have been designed to encapsulate neurotherapeutics, including small molecules, proteins, and nucleic acids, ensuring their delivery to the target brain regions. Once the nanoparticles cross the BBB, they can release the therapeutic agents in a controlled manner, enhancing the treatment of neurological diseases such as Alzheimer’s disease, Parkinson’s disease, and brain tumors. Moreover, nanoparticles enable targeted delivery, reducing the systemic toxicity often associated with CNS drugs. Through innovative design, nanoparticles also offer potential for the delivery of gene therapies, RNA-based treatments, and even diagnostic agents for CNS conditions. This approach is revolutionizing treatments for neurological disorders, offering new hope for patients with diseases that have historically been difficult to treat due to the BBB(65).

Multifunctional Nanoparticles:

The concept of theranostics the combination of therapeutic and diagnostic capabilities in a single system has gained significant attention in nanomedicine, and multifunctional nanoparticles are at the forefront of this innovation(66). These nanoparticles can be engineered to serve dual purposes: delivering therapeutic agents to specific sites while simultaneously providing diagnostic information, such as imaging or monitoring the drug’s effect.

Multifunctional nanoparticles often incorporate therapeutic agents (such as drugs, genes, or siRNA), imaging agents (e.g., fluorescent dyes, magnetic resonance imaging (MRI) contrast agents, or radioisotopes), and targeting ligands into a single nanoparticle platform. This integration allows for real-time tracking of the drug delivery process, enabling clinicians to monitor the distribution, release, and effectiveness of the drug at the target site. Multifunctional nanoparticles are particularly beneficial in oncology, where they can deliver chemotherapy agents directly to tumor cells while simultaneously enabling non-invasive imaging for early detection, monitoring treatment response, and assessing drug delivery efficiency. Additionally, these nanoparticles can provide personalized treatment strategies, allowing adjustments based on the diagnostic information obtained during therapy. In gene therapy, multifunctional nanoparticles can deliver genetic material and simultaneously monitor the gene-editing process or the gene's therapeutic effect. The combination of therapeutic and diagnostic functions not only improves the accuracy of drug delivery but also facilitates personalized medicine, making it an exciting advancement in nanomedicine(67).

5. Challenges in Nanoparticle-Based Drug Delivery

Toxicity and Biocompatibility:

One of the primary concerns in nanoparticle-based drug delivery is the potential toxicity and biocompatibility of the nanoparticles. While nanoparticles offer promising therapeutic advantages, their small size and unique properties can also lead to unforeseen interactions with biological systems(68). These interactions may result in cytotoxicity, immunotoxicity, or even genotoxicity. The materials used for nanoparticle synthesis, such as metals, lipids, or polymers, may have adverse effects on cells, tissues, or organs if they accumulate in the body over time. Additionally, the surface properties of nanoparticles, such as charge, shape, and functionalization, can influence their interaction with immune cells, leading to an immune response that may cause inflammation or allergic reactions(69). In some cases, nanoparticles may be cleared by the reticuloendothelial system (RES), causing organ-specific toxicity, particularly to the liver or spleen. To mitigate these risks, extensive in vitro and in vivo toxicity studies are required to assess the safety profiles of nanoparticles. Biocompatibility can be improved through surface modifications like PEGylation (attachment of polyethylene glycol), which reduces protein adsorption and minimizes immune recognition. However, ensuring long-term safety remains a challenge, especially as nanoparticles accumulate in tissues or organs over time. These concerns must be carefully addressed before nanoparticles can be widely adopted for clinical use(70).

Scalability and Manufacturing Issues:

While nanoparticles offer numerous advantages in drug delivery, scaling up their production for commercial use presents significant challenges. The synthesis of nanoparticles often involves complex and precise methods, such as solvent evaporation, nanoprecipitation, or emulsification, which may be difficult to replicate on a large scale(71). As nanoparticle formulations are often tailored to specific drugs and therapeutic needs, achieving batch-to-batch consistency can be difficult. Additionally, maintaining uniform size, shape, and surface properties is critical for the stability and effectiveness of the nanoparticles, yet this is harder to control at a larger scale. This variability can lead to variations in drug loading, release profiles, and therapeutic efficacy. Manufacturing processes for nanoparticles often require specialized equipment and reagents, increasing production costs. Furthermore, as nanoparticles are often

made from biodegradable or bioresorbable materials, maintaining the stability and purity of raw materials during manufacturing can be challenging. There are also regulatory challenges associated with scaling up production. The cost-effectiveness of large-scale production remains a significant hurdle, particularly for nanoparticles used in complex formulations like lipid nanoparticles (LNPs) in mRNA vaccines. Addressing these scalability and manufacturing issues is crucial for ensuring that nanoparticle-based drug delivery systems can be produced in large quantities at affordable prices for clinical applications(68).

Regulatory Considerations:

The regulatory pathway for nanoparticle-based drug delivery systems is complex, involving rigorous assessments to ensure the safety, efficacy, and quality of these innovative therapies. Nanoparticles are considered a class of drug delivery systems that may fall under both the regulatory frameworks for pharmaceuticals and medical devices, depending on their intended use(72). In the United States, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provide guidelines for the approval of nanomedicines. Nanoparticles used for drug delivery must undergo extensive preclinical studies, including toxicology, pharmacokinetics, and biodistribution assessments. The regulatory process also includes the evaluation of manufacturing practices, quality control, and consistency in production. Additionally, the FDA has issued specific guidelines on the characterization of nanoparticles, including their size, surface charge, and morphology, which may influence their safety and efficacy(73). Given the novelty and unique properties of nanoparticles, there is a need for updated and specialized regulatory frameworks to address the challenges of nanoparticle drug delivery. The regulatory agencies also consider the potential long-term effects of nanoparticles, such as bioaccumulation and immunogenicity, which may not have been fully understood during preclinical trials. As nanoparticle-based drug delivery systems continue to advance, regulators are increasingly focused on developing flexible and comprehensive guidelines to ensure the safe translation of these systems from the lab to clinical practice(74).

Stability and Storage:

The stability and storage of nanoparticles are major concerns in their clinical and commercial application. Nanoparticles are highly sensitive to environmental conditions, and their stability can be affected by factors such as temperature, humidity, and light. Nanoparticles may aggregate or degrade over time, reducing their efficacy and altering their drug release profiles. For instance, nanoparticles that are susceptible to aggregation may lose their size and surface properties, leading to reduced bioavailability or altered pharmacokinetics. This is especially a concern for nanoparticles used in complex drug delivery systems, such as liposomes or polymeric nanoparticles, where stability is essential for consistent therapeutic outcomes(75, 76). Additionally, the formulation of nanoparticles often involves the use of surfactants or stabilizers, which can affect their long-term storage stability(77, 78). When exposed to unfavorable conditions during transportation or storage, nanoparticles may undergo physical or chemical changes that compromise their functionality. To maintain nanoparticle stability, several strategies are employed, such as lyophilization (freeze-drying) or the addition of stabilizing agents(79, 80). However, the shelf life of nanoparticles can still be limited, and careful consideration of their storage conditions is required. For clinical applications, it is crucial that nanoparticles remain stable throughout their shelf life and during transportation

from manufacturing sites to hospitals or pharmacies. The development of nanoparticle formulations with improved stability profiles is essential to ensure their effectiveness and safety during storage and use, addressing a critical challenge in the commercialization of nanoparticle-based drug delivery systems(81, 82).

6. Future Directions and Prospects

Personalized Nanomedicine:

Personalized nanomedicine represents a transformative approach to treatment, where nanoparticles are tailored to the specific genetic, molecular, and environmental characteristics of an individual patient(83). This strategy enables more effective and precise therapeutic interventions, as it considers the unique aspects of a patient's condition, such as genetic mutations, biomarker profiles, and disease progression. Nanoparticles can be engineered to deliver drugs or therapies specifically to the patient's disease site, minimizing side effects and maximizing therapeutic outcomes(84, 85). In cancer treatment, for example, nanoparticles can be functionalized with ligands or antibodies that specifically bind to receptors overexpressed on the patient's tumor cells. Personalized nanomedicine also extends to gene therapies, where nanoparticles can be designed to deliver genetic material in a way that addresses the individual genetic profile of the patient, thus improving the precision of gene editing or RNA therapies(86). Moreover, the combination of nanoparticle-based systems with diagnostic tools can allow for real-time monitoring of drug efficacy and disease progression, further improving treatment outcomes(87). As the field of genomics advances, the ability to customize nanoparticle formulations based on individual patient data will revolutionize the treatment of many diseases, from cancer to genetic disorders, offering a more patient-centric approach and paving the way for truly personalized treatments(88).

Nanotechnology in Combination Therapies:

Emerging trends in nanotechnology are increasingly focusing on combination therapies, where nanoparticles are used to deliver multiple therapeutic agents simultaneously to achieve enhanced efficacy(89). Combination therapies, such as chemotherapy combined with immunotherapy, offer a synergistic approach to treating complex diseases like cancer. Nanoparticles are particularly suited for this application as they can simultaneously encapsulate multiple drugs, targeting different pathways in the disease process. For example, nanoparticles can deliver a chemotherapy drug to reduce tumor size while simultaneously carrying immune checkpoint inhibitors or cytokines to activate the immune system against cancer cells(90). This dual approach enhances treatment efficacy by tackling the disease from different angles, increasing the likelihood of a positive response and overcoming resistance mechanisms. Nanoparticles also improve the pharmacokinetics of combination therapies by ensuring that both drugs are released at the same site in a controlled manner, avoiding the toxicities associated with systemic drug distribution. The use of nanoparticles in combination therapies has shown promising results in preclinical studies and early-phase clinical trials, especially in cancer and infectious diseases. As research continues to explore the best combinations of therapeutic agents, nanoparticle-based combination therapies are expected to play a significant role in providing more effective and personalized treatment options for a wide range of diseases.

Advances in Nanoparticle Design:

Nanoparticle design continues to evolve with exciting advancements that are likely to shape the future of drug delivery. One promising area is the development of self-assembled nanoparticles. These nanoparticles are formed through spontaneous molecular interactions, such as hydrophobic, electrostatic, or hydrogen bonding forces, without the need for complex synthetic procedures. Self-assembly offers an efficient and cost-effective method for producing nanoparticles with high stability, uniformity, and customizable properties, making them ideal for drug delivery applications. Another important innovation is the creation of biodegradable nanoparticles. These nanoparticles break down into non-toxic byproducts after fulfilling their drug delivery role, reducing the risk of long-term accumulation and toxicity in the body. Biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), are commonly used in these systems. Furthermore, advances in AI-driven design are accelerating the development of nanoparticles with optimized properties. Machine learning algorithms and AI tools can predict the behavior of nanoparticles in biological systems, such as drug release kinetics, bioavailability, and targeting efficiency(91). This allows researchers to design nanoparticles with precise characteristics tailored to specific therapeutic needs. AI-driven design can also streamline the discovery of new nanomaterials, enabling the rapid development of nanoparticles with enhanced therapeutic performance. As these innovative technologies progress, nanoparticle design will become more sophisticated, enabling highly efficient, targeted, and personalized drug delivery systems for a wide range of diseases.

Clinical Translation and Market Readiness:

The clinical translation and market readiness of nanoparticle-based drug delivery systems face several challenges, including regulatory hurdles, manufacturing scale-up, and cost-effectiveness. While nanoparticles have shown great promise in preclinical and early-phase clinical trials, their successful transition into widespread clinical use requires rigorous testing for safety, efficacy, and stability. Clinical trials must demonstrate that nanoparticle formulations are not only effective but also safe for human use, particularly with regard to long-term exposure and potential accumulation in tissues. Regulatory bodies such as the FDA and EMA are working to establish clearer guidelines for the approval of nanomedicines, but the process remains complex due to the unique properties of nanoparticles and their potential for varied biological interactions(92). Furthermore, scaling up the production of nanoparticles presents manufacturing challenges, as the synthesis of nanoparticles must be reproducible and cost-effective. Current methods for large-scale production often struggle with maintaining consistency in particle size, drug loading, and surface characteristics. For nanoparticle-based therapies to be commercially viable, improvements in manufacturing processes are necessary to reduce costs and improve scalability. Market readiness also involves establishing clear pricing structures, reimbursement models, and educational efforts to ensure that clinicians and patients are aware of the benefits and risks of nanoparticle-based treatments. As these issues are addressed, the clinical translation of nanoparticle-based drug delivery systems is expected to expand, offering new therapeutic possibilities for diseases that have been difficult to treat with conventional drug delivery methods(93).

Conclusion:

Nanoparticle-based drug delivery systems have emerged as a transformative innovation in modern therapeutics, offering precise drug targeting, controlled release, and improved bioavailability. These nano-sized carriers, including liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles, enable efficient drug delivery for treating various diseases, particularly cancer, neurological disorders, and genetic conditions. Their ability to bypass biological barriers, such as the blood-brain barrier, and provide site-specific drug release significantly enhances therapeutic efficacy while reducing systemic toxicity. Despite these advantages, challenges persist. Issues related to toxicity, immunogenicity, large-scale manufacturing, and regulatory approvals need to be addressed to facilitate clinical translation. Stability and storage constraints also pose limitations on the widespread adoption of nanoparticle-based formulations. However, continuous advancements in personalized medicine, AI-driven nanotechnology, and combination therapies are propelling the field toward more effective and patient-centric treatment options. The future of nanoparticle-based drug delivery lies in integrating novel materials, precision targeting strategies, and real-time diagnostic capabilities, ultimately leading to the development of theranostic platforms. As research progresses, overcoming current barriers will enable nanoparticles to become a standard component of modern medicine, transforming drug delivery paradigms and enhancing patient outcomes.

References:

1. Jain KK. An overview of drug delivery systems. Drug delivery systems. 2020:1-54.
2. Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. Journal of Controlled Release. 2014;190:15-28.
3. Ibeanu N, Egbu R, Onyekuru L, Javaheri H, Tee Khaw P, R. Williams G, et al. Injectables and depots to prolong drug action of proteins and peptides. Pharmaceutics. 2020;12(10):999.
4. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905.
5. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. Journal of internal medicine. 2015;278(4):369-95.
6. Padma VV. An overview of targeted cancer therapy. BioMedicine. 2015;5:1-6.
7. Kumar KS, Bhowmik D, Srivastava S, Paswan S, Dutta AS. Sustained release drug delivery system potential. The pharma innovation. 2012;1(2).
8. Sahoo SK, Jain TK, Reddy MK, Labhasetwar V. Nano-sized carriers for drug delivery. NanoBioTechnology: BioInspired Devices and Materials of the Future. 2008:329-48.
9. Tsou YH, Zhang XQ, Zhu H, Syed S, Xu X. Drug delivery to the brain across the blood–brain barrier using nanomaterials. Small. 2017;13(43):1701921.
10. Barua S, Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano today. 2014;9(2):223-43.
11. Bai X, Smith ZL, Wang Y, Butterworth S, Tirella A. Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review. Micromachines. 2022;13(10):1623.
12. Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chemical reviews. 2017;117(19):12133-64.
13. Raheem SMA, Al-zahraa JJ, Jasem AJ, Hasan NF. Advancements in Nanotechnology-Based Drug Delivery Systems for Oral Healthcare: From Traditional Practices to Personalized Medicine: A REVIEW. Al-Bayan Journal for Medical and Health Sciences. 2024;3(1):24-37.
14. Yadav D, Sandeep K, Pandey D, Dutta RK. Liposomes for drug delivery. J Biotechnol Biomater. 2017;7(04):276.
15. Branco MC, Schneider JP. Self-assembling materials for therapeutic delivery. Acta biomaterialia. 2009;5(3):817-31.
16. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Current drug delivery. 2005;2(4):369-81.
17. Anarjan FS. Active targeting drug delivery nanocarriers: Ligands. Nano-Structures & Nano-Objects. 2019;19:100370.
18. Forssen E, Willis M. Ligand-targeted liposomes. Advanced drug delivery reviews. 1998;29(3):249-71.
19. Marchal S, Hor AE, Millard M, Gillon V, Bezdetnaya L. Anticancer drug delivery: an update on clinically applied nanotherapeutics. Drugs. 2015;75:1601-11.
20. Elmowafy M, Shalaby K, Elkomy MH, Alsaidan OA, Gomaa HA, Abdelgawad MA, Mostafa EM. Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges. Polymers. 2023;15(5):1123.
21. Perinelli DR, Cespi M, Bonacucina G, Palmieri GF. PEGylated polylactide (PLA) and poly (lactic-co-glycolic acid)(PLGA) copolymers for the design of drug delivery systems. Journal of pharmaceutical investigation. 2019;49:443-58.
22. Vilar G, Tulla-Puche J, Albericio F. Polymers and drug delivery systems. Current drug delivery. 2012;9(4):367-94.
23. Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181(1):151-67.

24. Peres LB, Peres LB, de Araújo PHH, Sayer C. Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique. Colloids and Surfaces B: Biointerfaces. 2016;140:317-23.
25. Mirchandani Y, Patravale VB, Brijesh S. Solid lipid nanoparticles for hydrophilic drugs. Journal of Controlled Release. 2021;335:457-64.
26. Ana Rd, Fonseca J, Karczewski J, Silva AM, Zielińska A, Souto EB. Lipid-based nanoparticulate systems for the ocular delivery of bioactives with anti-inflammatory properties. International Journal of Molecular Sciences. 2022;23(20):12102.
27. Hsu HJ, Bugno J, Lee Sr, Hong S. Dendrimer-based nanocarriers: a versatile platform for drug delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2017;9(1):e1409.
28. Varma AK, Goyal B, Chaurasia P, Mandloi N, Meval A. Nanoscale Dendrimers in Targeted Drug Delivery: A Systematic Review. Lipid Based Nanocarriers for Drug Delivery. 2024:305.
29. Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22(9):1401.
30. Gigliobianco MR, Casadidio C, Censi R, Di Martino P. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018;10(3):134.
31. Gao L, Liu G, Ma J, Wang X, Zhou L, Li X, Wang F. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharmaceutical research. 2013;30:307-24.
32. Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian journal of pharmaceutical sciences. 2015;10(1):13-23.
33. Bu X, Ji N, Dai L, Dong X, Chen M, Xiong L, Sun Q. Self-assembled micelles based on amphiphilic biopolymers for delivery of functional ingredients. Trends in Food Science & Technology. 2021;114:386-98.
34. Gupta N, Gupta SM, Sharma S. Carbon nanotubes: Synthesis, properties and engineering applications. Carbon Letters. 2019;29:419-47.
35. Liu L, Ma W, Zhang Z. Macroscopic carbon nanotube assemblies: preparation, properties, and potential applications. Small. 2011;7(11):1504-20.
36. Tomar A, Garg G. Short review on application of gold nanoparticles. Global Journal of Pharmacology. 2013;7(1):34-8.
37. Ummadi S, Shravani B, Rao N, Reddy MS, Sanjeev B. Overview on controlled release dosage form. System. 2013;7(8):51-60.
38. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature materials. 2013;12(11):991-1003.
39. Abdella S, Abid F, Youssef SH, Kim S, Afinjuomo F, Malinga C, et al. pH and its applications in targeted drug delivery. Drug Discovery Today. 2023;28(1):103414.
40. Karimi M, Sahandi Zangabad P, Ghasemi A, Amiri M, Bahrami M, Malekzad H, et al. Temperature-responsive smart nanocarriers for delivery of therapeutic agents: applications and recent advances. ACS applied materials & interfaces. 2016;8(33):21107-33.
41. Li M, Zhao G, Su W-K, Shuai Q. Enzyme-responsive nanoparticles for anti-tumor drug delivery. Frontiers in chemistry. 2020;8:647.
42. Li Z, Li Y, Chen C, Cheng Y. Magnetic-responsive hydrogels: From strategic design to biomedical applications. Journal of Controlled Release. 2021;335:541-56.
43. Nag S, Mohanto S, Ahmed MG, Subramaniyan V. “Smart” stimuli-responsive biomaterials revolutionizing the theranostic landscape of inflammatory arthritis. Materials Today Chemistry. 2024;39:102178.

44. Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. Journal of Pharmacy and Pharmacology. 2019;71(8):1185-98.
45. Zi Y, Yang K, He J, Wu Z, Liu J, Zhang W. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Advanced Drug Delivery Reviews. 2022;188:114449.
46. M Rabanel J, Aoun V, Elkin I, Mokhtar M, Hildgen P. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. Current medicinal chemistry. 2012;19(19):3070-102.
47. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacological research. 2010;62(2):90-9.
48. Kaur N, Popli P, Tiwary N, Swami R. Small molecules as cancer targeting ligands: Shifting the paradigm. Journal of Controlled Release. 2023;355:417-33.
49. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Drug delivery. 2010:3-53.
50. Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale research letters. 2021;16(1):173.
51. Akhtar MJ, Ahamed M, Alhadlaq HA, Alrokayan SA, Kumar S. Targeted anticancer therapy: overexpressed receptors and nanotechnology. Clinica chimica acta. 2014;436:78-92.
52. Andretto V, Dusi S, Zilio S, Repellin M, Kryza D, Ugel S, Lollo G. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: from conventional to cutting edge in biologics and RNA-based nanomedicines. Advanced Drug Delivery Reviews. 2023:115080.
53. Amer MH. Gene therapy for cancer: present status and future perspective. Molecular and cellular therapies. 2014;2:1-19.
54. Parvin N, Joo SW, Mandal TK. Enhancing Vaccine Efficacy and Stability: A Review of the Utilization of Nanoparticles in mRNA Vaccines. Biomolecules. 2024;14(8):1036.
55. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024:105338.
56. Murthy NTV, Vlasova K, Renner J, Jozic A, Sahay G. A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines. Advanced Drug Delivery Reviews. 2024:115305.
57. Liu C, Zhang N. Nanoparticles in gene therapy: principles, prospects, and challenges. Progress in molecular biology and translational science. 2011;104:509-62.
58. Bezbaruah R, Chavda VP, Nongrang L, Alom S, Deka K, Kalita T, et al. Nanoparticle-based delivery systems for vaccines. Vaccines. 2022;10(11):1946.
59. Akagi T, Baba M, Akashi M. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Polymers in nanomedicine. 2012:31-64.
60. Khurana A, Allawadhi P, Khurana I, Allwadhi S, Weiskirchen R, Banothu AK, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today. 2021;38:101142.
61. Parvin N, Mandal TK, Joo S-W. The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems. Pharmaceutics. 2024;16(11):1366.
62. Shetty S, Alvarado PC, Pettie D, Collier JH. Next-generation Vaccine Development with nanomaterials: recent advances, possibilities, and challenges. Annual Review of Biomedical Engineering. 2024;26(1):273-306.
63. Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. BioMed research international. 2014;2014(1):869269.

64. Zhou Y, Peng Z, Seven ES, Leblanc RM. Crossing the blood-brain barrier with nanoparticles. Journal of controlled release. 2018;270:290-303.
65. Moura RP, Martins C, Pinto S, Sousa F, Sarmento B. Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert opinion on drug delivery. 2019;16(3):271-85.
66. Panda S, Hajra S, Kaushik A, Rubahn H, Mishra Y, Kim H. Smart nanomaterials as the foundation of a combination approach for efficient cancer theranostics. Materials Today Chemistry. 2022;26:101182.
67. Park K, Lee S, Kang E, Kim K, Choi K, Kwon IC. New generation of multifunctional nanoparticles for cancer imaging and therapy. Advanced functional materials. 2009;19(10):1553-66.
68. Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomedical Technology. 2024;5:109-22.
69. Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2(4):MR17-MR71.
70. Meyers SR, Grinstaff MW. Biocompatible and bioactive surface modifications for prolonged in vivo efficacy. Chemical reviews. 2012;112(3):1615-32.
71. Pulingam T, Foroozandeh P, Chuah J-A, Sudesh K. Exploring various techniques for the chemical and biological synthesis of polymeric nanoparticles. Nanomaterials. 2022;12(3):576.
72. Ragelle H, Danhier F, Préat V, Langer R, Anderson DG. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert opinion on drug delivery. 2017;14(7):851-64.
73. Desai N. Challenges in development of nanoparticle-based therapeutics. The AAPS journal. 2012;14(2):282-95.
74. Anklam E, Bahl MI, Ball R, Beger RD, Cohen J, Fitzpatrick S, et al. Emerging technologies and their impact on regulatory science. Experimental Biology and Medicine. 2022;247(1):1-75.
75. Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. International journal of pharmaceutics. 2021;601:120571.
76. Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric lipid hybrid nanoparticles (plns) as emerging drug delivery platform—A comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics. 2021;13(8):1291.
77. Sultana S, Alzahrani N, Alzahrani R, Alshamrani W, Aloufi W, Ali A, et al. Stability issues and approaches to stabilised nanoparticles based drug delivery system. Journal of drug targeting. 2020;28(5):468-86.
78. Kovacevic A, Savic S, Vuleta G, Mueller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. International journal of pharmaceutics. 2011;406(1-2):163-72.
79. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Advanced drug delivery reviews. 2006;58(15):1688-713.
80. Abla KK, Mehanna MM. Freeze-drying: A flourishing strategy to fabricate stable pharmaceutical and biological products. International journal of pharmaceutics. 2022;628:122233.
81. Kumar R, Dalvi SV, Siril PF. Nanoparticle-based drugs and formulations: current status and emerging applications. ACS Applied Nano Materials. 2020;3(6):4944-61.
82. Soliman GM. Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges. International journal of pharmaceutics. 2017;523(1):15-32.

83. Fornaguera C, García-Celma MJ. Personalized nanomedicine: a revolution at the nanoscale. Journal of personalized medicine. 2017;7(4):12.
84. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nature reviews drug discovery. 2021;20(2):101-24.
85. Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H, Qoronfleh MW. Therapeutic efficacy of nanoparticles and routes of administration. Biomaterials research. 2019;23(1):20.
86. Alghamdi MA, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The promise of nanotechnology in personalized medicine. Journal of personalized medicine. 2022;12(5):673.
87. Singh V. Theranostics: Integrated Diagnostics and Therapy Using Nanomedicine. Nanomedicine: Springer; 2024. p. 505-30.
88. Sakamoto JH, van de Ven AL, Godin B, Blanco E, Serda RE, Grattoni A, et al. Enabling individualized therapy through nanotechnology. Pharmacological research. 2010;62(2):57-89.
89. Kemp JA, Shim MS, Heo CY, Kwon YJ. “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Advanced drug delivery reviews. 2016;98:3-18.
90. Afshari AR, Sanati M, Mollazadeh H, Kesharwani P, Johnston TP, Sahebkar A, editors. Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways. Seminars in cancer biology; 2022: Elsevier.
91. Heydari S, Masoumi N, Esmaeeli E, Ayyoubzadeh SM, Ghorbani-Bidkorpeh F, Ahmadi M. Artificial intelligence in nanotechnology for treatment of diseases. Journal of Drug Targeting. 2024;32(10):1247-66.
92. Sainz V, Conniot J, Matos AI, Peres C, Zupanǒiǒ E, Moura L, et al. Regulatory aspects on nanomedicines. Biochemical and biophysical research communications. 2015;468(3):504-10.
93. Oualikene-Gonin W, Sautou V, Ezan E, Bastos H, Bellissant E, Belgodère L, et al. Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products. Frontiers in Public Health. 2023;11:1125577.